{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2023:UUO524DPZZIOUKDT4EJIV3PLOL","short_pith_number":"pith:UUO524DP","canonical_record":{"source":{"id":"2312.15396","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-12-24T03:38:46Z","cross_cats_sorted":[],"title_canon_sha256":"786d83a8d078630c96b50f06bfe17634161c7fa19bfab55b83e5bac9fc8c8d5b","abstract_canon_sha256":"8eac9271bbcaddb478519daed5b7855b9b7024d0ac0fdcf18490058e1c0fade8"},"schema_version":"1.0"},"canonical_sha256":"a51ddd706fce50ea2873e1128aedeb72e1319952a285affb7cc45166312de61a","source":{"kind":"arxiv","id":"2312.15396","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2312.15396","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"arxiv_version","alias_value":"2312.15396v1","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2312.15396","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"pith_short_12","alias_value":"UUO524DPZZIO","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"pith_short_16","alias_value":"UUO524DPZZIOUKDT","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"pith_short_8","alias_value":"UUO524DP","created_at":"2026-07-05T07:27:56Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2023:UUO524DPZZIOUKDT4EJIV3PLOL","target":"record","payload":{"canonical_record":{"source":{"id":"2312.15396","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-12-24T03:38:46Z","cross_cats_sorted":[],"title_canon_sha256":"786d83a8d078630c96b50f06bfe17634161c7fa19bfab55b83e5bac9fc8c8d5b","abstract_canon_sha256":"8eac9271bbcaddb478519daed5b7855b9b7024d0ac0fdcf18490058e1c0fade8"},"schema_version":"1.0"},"canonical_sha256":"a51ddd706fce50ea2873e1128aedeb72e1319952a285affb7cc45166312de61a","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T07:27:56.036974Z","signature_b64":"wV+Heo9+6MX/zdJ8I+vrZhGiy//OD2iF1rkfehVV0fgrYJq6DA8k/Q7dZu48nS7j8MItoOaGPQ7m3yiVecjwBw==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"a51ddd706fce50ea2873e1128aedeb72e1319952a285affb7cc45166312de61a","last_reissued_at":"2026-07-05T07:27:56.036496Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T07:27:56.036496Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"2312.15396","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T07:27:56Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"/qDJ5Itr9tpCROqMFCV/xuVPlI/NeuEWUwTL5a6S0m1Emb6lqoq6MtcS1fBrnHRw6zxb6rhuy1ky13qlEZdLBA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-07T10:54:02.981692Z"},"content_sha256":"53e4ee4446636671383e016fe73a0d6117498a0659ecf861741f24b7fc1585c1","schema_version":"1.0","event_id":"sha256:53e4ee4446636671383e016fe73a0d6117498a0659ecf861741f24b7fc1585c1"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2023:UUO524DPZZIOUKDT4EJIV3PLOL","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"PKBOIN-12: A Bayesian optimal interval Phase I/II design incorporating pharmacokinetics outcomes to find the optimal biological dose","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"stat.ME","authors_text":"Hao Sun, Jieqi Tu","submitted_at":"2023-12-24T03:38:46Z","abstract_excerpt":"Immunotherapies and targeted therapies have gained popularity due to their promising therapeutic effects across multiple treatment areas. The focus of early phase dose-finding clinical trials has shifted from finding the maximum tolerated dose (MTD) to identifying the optimal biological dose (OBD), which aims to balance the toxicity and efficacy outcomes, thereby optimizing the risk-benefit trade-off. These trials often collect multiple pharmacokinetics (PK) outcomes to assess drug exposure, which has shown correlations with toxicity and efficacy outcomes but has not been utilized in the curre"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2312.15396","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2312.15396/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T07:27:56Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"e4REB1GtQX1rC/GXIl+hpVZ21Q0WYjeRFvZBKwqNUJHZMu3peL4yKT1o9Ong7X9iQYeCcvW8dCcBzGzcWrnIDQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-07T10:54:02.982197Z"},"content_sha256":"0fdfdd52c1ca553922643aba357d92588810aa5b002d5fe73556a10e9329bc1c","schema_version":"1.0","event_id":"sha256:0fdfdd52c1ca553922643aba357d92588810aa5b002d5fe73556a10e9329bc1c"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/UUO524DPZZIOUKDT4EJIV3PLOL/bundle.json","state_url":"https://pith.science/pith/UUO524DPZZIOUKDT4EJIV3PLOL/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/UUO524DPZZIOUKDT4EJIV3PLOL/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-08-07T10:54:02Z","links":{"resolver":"https://pith.science/pith/UUO524DPZZIOUKDT4EJIV3PLOL","bundle":"https://pith.science/pith/UUO524DPZZIOUKDT4EJIV3PLOL/bundle.json","state":"https://pith.science/pith/UUO524DPZZIOUKDT4EJIV3PLOL/state.json","well_known_bundle":"https://pith.science/.well-known/pith/UUO524DPZZIOUKDT4EJIV3PLOL/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2023:UUO524DPZZIOUKDT4EJIV3PLOL","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"8eac9271bbcaddb478519daed5b7855b9b7024d0ac0fdcf18490058e1c0fade8","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-12-24T03:38:46Z","title_canon_sha256":"786d83a8d078630c96b50f06bfe17634161c7fa19bfab55b83e5bac9fc8c8d5b"},"schema_version":"1.0","source":{"id":"2312.15396","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2312.15396","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"arxiv_version","alias_value":"2312.15396v1","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2312.15396","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"pith_short_12","alias_value":"UUO524DPZZIO","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"pith_short_16","alias_value":"UUO524DPZZIOUKDT","created_at":"2026-07-05T07:27:56Z"},{"alias_kind":"pith_short_8","alias_value":"UUO524DP","created_at":"2026-07-05T07:27:56Z"}],"graph_snapshots":[{"event_id":"sha256:0fdfdd52c1ca553922643aba357d92588810aa5b002d5fe73556a10e9329bc1c","target":"graph","created_at":"2026-07-05T07:27:56Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"integrity":{"available":true,"clean":true,"detectors_run":[],"endpoint":"/pith/2312.15396/integrity.json","findings":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938","summary":{"advisory":0,"by_detector":{},"critical":0,"informational":0}},"paper":{"abstract_excerpt":"Immunotherapies and targeted therapies have gained popularity due to their promising therapeutic effects across multiple treatment areas. The focus of early phase dose-finding clinical trials has shifted from finding the maximum tolerated dose (MTD) to identifying the optimal biological dose (OBD), which aims to balance the toxicity and efficacy outcomes, thereby optimizing the risk-benefit trade-off. These trials often collect multiple pharmacokinetics (PK) outcomes to assess drug exposure, which has shown correlations with toxicity and efficacy outcomes but has not been utilized in the curre","authors_text":"Hao Sun, Jieqi Tu","cross_cats":[],"headline":"","license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-12-24T03:38:46Z","title":"PKBOIN-12: A Bayesian optimal interval Phase I/II design incorporating pharmacokinetics outcomes to find the optimal biological dose"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2312.15396","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:53e4ee4446636671383e016fe73a0d6117498a0659ecf861741f24b7fc1585c1","target":"record","created_at":"2026-07-05T07:27:56Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"8eac9271bbcaddb478519daed5b7855b9b7024d0ac0fdcf18490058e1c0fade8","cross_cats_sorted":[],"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2023-12-24T03:38:46Z","title_canon_sha256":"786d83a8d078630c96b50f06bfe17634161c7fa19bfab55b83e5bac9fc8c8d5b"},"schema_version":"1.0","source":{"id":"2312.15396","kind":"arxiv","version":1}},"canonical_sha256":"a51ddd706fce50ea2873e1128aedeb72e1319952a285affb7cc45166312de61a","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"a51ddd706fce50ea2873e1128aedeb72e1319952a285affb7cc45166312de61a","first_computed_at":"2026-07-05T07:27:56.036496Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-07-05T07:27:56.036496Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"wV+Heo9+6MX/zdJ8I+vrZhGiy//OD2iF1rkfehVV0fgrYJq6DA8k/Q7dZu48nS7j8MItoOaGPQ7m3yiVecjwBw==","signature_status":"signed_v1","signed_at":"2026-07-05T07:27:56.036974Z","signed_message":"canonical_sha256_bytes"},"source_id":"2312.15396","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:53e4ee4446636671383e016fe73a0d6117498a0659ecf861741f24b7fc1585c1","sha256:0fdfdd52c1ca553922643aba357d92588810aa5b002d5fe73556a10e9329bc1c"],"state_sha256":"2772fb528384f3349fc23df250d2a99c166f41803121f3198782b3956a7ada49"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"8TMis10jwur5NTQx+QCvWh0dv4qHqkAMNhNd2VJZIc17TsAj08PpbME02St3WdfGI5EMfkEjecQq4h/W8KOhBg==","signed_message":"bundle_sha256_bytes","signed_at":"2026-08-07T10:54:02.987057Z","bundle_sha256":"93b284d0d6cfee2892d1a1411edd12771d3a1d40959da57990cffb40bbd64760"}}